Ll. Barrickman et al., BUPROPION VERSUS METHYLPHENIDATE IN THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER, Journal of the American Academy of Child and Adolescent Psychiatry, 34(5), 1995, pp. 649-657
Objective: In the treatment of attention-deficit hyperactivity disorde
r (ADHD), the efficacy of the tricyclic antidepressants and monoamine
oxidase inhibitor antidepressants has been compared with that of both
placebo and the stimulants (methylphenidate and/or dextroamphetamine).
However, the effectiveness of bupropion has been contrasted only with
placebo. The primary aim of this study was to contrast the efficacy o
f bupropion with that of methylphenidate in the treatment of ADHD. Met
hod: A double-blind, crossover design was used in this study. After a
14-day medication washout period, 15 ADHD subjects (7 to 17 years old)
were randomized to either methylphenidate or bupropion for 6 weeks, w
ashed out for an additional 2 weeks, and then ''crossed over'' to the
other drug. Methylphenidate was titrated to the maximum effective dose
of 0.4 to 1.3 mg/kg per day (mean 0.7 mg/kg per day) and bupropion wa
s titrated to an effective dose ranging from 1.4 to 5.7 mg/kg per day
(mean 3.3 mg/kg per day). Results: Both methylphenidate and bupropion
produced significantly greater (p<.001) and equivalent improvement on
the Iowa-Conners Teacher's Rating Scale according to both the subjects
' parents and teachers. The same pattern of improvement was also noted
for improvement on the Clinical Global Impression Scale, Kagan's Matc
hing Familiar Figures Test, Continuous Performance Test, Children's De
pression Inventory, Children's Manifest Anxiety Scale, and Rey Auditor
y-Verbal Learning Test. Conclusions: In this double-blind, crossover t
rial, bupropion and methylphenidate were both effective and did not di
ffer in their overall efficacy as treatments for ADHD.